Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Ganoderma lucidum supplement for people with metabolic fatty liver disease

Tests Ganoderma lucidum against a placebo in adults with metabolic fatty liver disease.

Plain-language title generated from the registry record
Registry title: Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)

Key facts

Where
Peshawar, PakistanSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 49 years old?

Source: NCT07564947, who can take part

Where in Pakistan

  • The University of Agriculture, PeshawarPeshawar, PakistanNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Agriculture, Peshawar
Trial code
NCT07564947
Record updated
4 May 2026
Original description
This RCT investigates the impact of Ganoderma lucidum on antioxidant staus, NRF2 levels and lipid metabolism in individuals with Metabolic Associated Fatty Liver Disease.Read full original descriptionShow less

Impatc of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease

This RCT investigates the impact of Ganoderma lucidum on antioxidant staus, NRF2 levels and lipid metabolism in individuals with Metabolic Associated Fatty Liver Disease.

Inclusion: Adults aged 35-49 years; Stage 1 and 2 fatty liver; Lipid profile test markers (elevated LDL, total cholesterol, or triglycerides less than 150mg/dL high 200-499mg/dL and 500 mg/dL are above high; Liver function test markers, ALT > 56 U/L, AST>40 U/L, ALP>147 UL; Inflammatory markers:TNF-α ≥8 pg/mL.

Exclusion: Participants having diabetes, psychological illness or depression, renal or cardiac disease, or other physiological conditions such as pregnancy, breastfeeding, or a history of stroke will excluded from this research.

ClinicalTrials.gov NCT07564947